Arun Banu, Austin Taylor, Babiera Gildy V, Basen-Engquist Karen, Carmack Cindy L, Chaoul Alejandro, Cohen Lorenzo, Connelly Lisa, Haddad Robin, Harrison Carol, Li Yisheng, Mallaiah Smitha, Nagarathna Raghuram, Parker Patricia A, Perkins George H, Reuben James M, Shih Ya-Chen Tina, Spelman Amy, Sood Anil, Yang Peiying, Yeung Sai-Ching J
1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2 Swami Vivekananda Yoga Anusandhana Samsthana, Bengaluru, India.
Integr Cancer Ther. 2017 Mar;16(1):3-20. doi: 10.1177/1534735416679516. Epub 2016 Nov 30.
Although epidemiological research demonstrates that there is an association between lifestyle factors and risk of breast cancer recurrence, progression of disease, and mortality, no comprehensive lifestyle change clinical trials have been conducted to determine if changing multiple risk factors leads to changes in biobehavioral processes and clinical outcomes in women with breast cancer. This article describes the design, feasibility, adherence to the intervention and data collection, and patient experience of a comprehensive lifestyle change clinical trial (CompLife).
CompLife is a randomized, controlled trial of a multiple-behavior intervention focusing on diet, exercise, and mind-body practice along with behavioral counseling to support change. The initial exposure to the intervention takes place during the 4 to 6 weeks of radiotherapy (XRT) for women with stage III breast cancer and then across the subsequent 12 months. The intervention group will have 42 hours of in-person lifestyle counseling during XRT (7-10 hours a week) followed by up to 30 hours of counseling via video connection for the subsequent 12 months (weekly sessions for 6 months and then monthly for 6 months). The primary outcome is disease-free survival. Multiple secondary outcomes are being evaluated, including: (1) biological pathways; (2) overall survival; (3) patient-reported outcomes; (4) dietary patterns/fitness levels, anthropometrics, and body composition; and (5) economic outcomes. Qualitative data of the patient experience in the trial is collected from exit interviews, concluding remarks, direct email correspondences, and web postings from patients.
Fifty-five patients have been recruited and randomized to the trial to date. Accrual of eligible patients is high (72%) and dropout rates extremely low (5%). Attendance to the in-person sessions is high (95% attending greater than 80% of sessions) as well as to the 30 hours of video counseling (88% attending more than 70% of sessions). Adherence to components of the behavior change intervention is high and compliance with the intensive amount of data collection is exceptional. Qualitative data collected from the participants reveals testimonials supporting the importance of the comprehensive nature of intervention, especially the mind-body/mindfulness component and social support, and meaningful lifestyle transformations.
Conducting a comprehensive, multicomponent, lifestyle change clinical trial for women with breast was feasible and collection of biobehavioral outcomes successful. Adherence to behavior change was high and patient experience was overwhelmingly positive.
尽管流行病学研究表明生活方式因素与乳腺癌复发风险、疾病进展及死亡率之间存在关联,但尚未开展全面的生活方式改变临床试验,以确定改变多种风险因素是否会导致乳腺癌女性的生物行为过程及临床结局发生变化。本文介绍了一项全面生活方式改变临床试验(CompLife)的设计、可行性、干预措施的依从性及数据收集情况,以及患者体验。
CompLife是一项随机对照试验,采用多行为干预,重点关注饮食、运动和身心锻炼,并提供行为咨询以支持改变。对于III期乳腺癌女性,干预措施的初始阶段在放疗(XRT)的4至6周内进行,随后持续12个月。干预组在放疗期间将接受42小时的面对面生活方式咨询(每周7至10小时),随后在接下来的12个月内通过视频连接接受长达30小时的咨询(前6个月每周一次,后6个月每月一次)。主要结局是无病生存期。正在评估多个次要结局,包括:(1)生物学途径;(2)总生存期;(3)患者报告的结局;(4)饮食模式/健康水平、人体测量指标和身体成分;(5)经济结局。通过退出访谈、总结发言、直接电子邮件通信以及患者的网络帖子收集试验中患者体验的定性数据。
迄今为止,已有55名患者被招募并随机分配至该试验。符合条件患者的入组率很高(72%),脱落率极低(5%)。面对面咨询课程的出勤率很高(95%的患者参加了超过80%的课程),30小时视频咨询课程的出勤率也很高(88%的患者参加了超过70%的课程)。行为改变干预措施各组成部分的依从性很高,对大量数据收集的合规性也非常出色。从参与者收集的定性数据显示,有证据支持干预措施全面性的重要性,尤其是身心/正念组成部分和社会支持,以及有意义的生活方式转变。
对乳腺癌女性进行全面、多组成部分的生活方式改变临床试验是可行的,生物行为结局的收集也很成功。行为改变的依从性很高,患者体验总体上是积极的。